# XYone Therapeutics, Inc: Phase 2 study started recruiting, 190 planned (MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | XYone Therapeutics, Inc |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Evaluation of XYA02 in Patients With Advanced Solid Tumors |
| NCT ID | NCT07670312 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; GEJ Adenocarcinoma; Colorectal Cancer; Pancreatic Adenocarcinoma |
| Intervention types | biological |
| Target enrollment | 190 |
| Site countries | Australia |
| Posted | 2026-06-26 |
| Planned start | 2026-09-17 |
| Event | Started recruiting |
| Event date | 2026-09-17 |
| Last update posted | 2026-09-25 |

## Why this score
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 2: multi-site, larger budget.
- 190 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07670312). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.